MEDIPOST Co., Ltd. (KOSDAQ:078160)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,950
+450 (2.09%)
At close: Feb 27, 2026
147.46%
Market Cap 857.93B
Revenue (ttm) 73.59B
Net Income (ttm) -97.90B
Shares Out 39.09M
EPS (ttm) -2,925.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 240,361
Average Volume 524,365
Open 22,100
Previous Close 21,500
Day's Range 21,200 - 22,550
52-Week Range 7,490 - 27,850
Beta 0.82
RSI 53.06
Earnings Date Mar 20, 2026

About MEDIPOST

MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 322
Stock Exchange KOSDAQ
Ticker Symbol 078160
Full Company Profile

Financial Performance

Financial Statements

News

BDA Advises MEDIPOST on Growth Capital Raise

New York, NY December 18, 2025 --(PR.com)-- BDA Partners is pleased to announce that its client MEDIPOST, a leading stem cell therapeutics & cord blood banking biotech company in Korea, has raised g...

2 months ago - Benzinga